We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rollover Protocol for Prior SU011248 Protocols

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00798889
First Posted: November 26, 2008
Last Update Posted: January 21, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
November 25, 2008
November 26, 2008
December 13, 2012
January 21, 2013
January 21, 2013
March 2004
December 2011   (Final data collection date for primary outcome measure)
Duration of Treatment [ Time Frame: Baseline up to Day 28 after last dose of study treatment ]
Continued access to SU011248 [ Time Frame: Duration of study ]
Complete list of historical versions of study NCT00798889 on ClinicalTrials.gov Archive Site
Not Provided
Collection of long term AE profile [ Time Frame: Last patient last visit ]
Not Provided
Not Provided
 
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Solid Tumors
Drug: Sunitinib
Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
Experimental: Sunitinib
Intervention: Drug: Sunitinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
314
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prior SU011248 Protocol.
  • Eligible to continue SU011248 treatment.

Exclusion Criteria:

  • Uncontrolled CNS metastasis.
  • Unfit to receive SU011248.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   France,   Greece,   Italy,   Netherlands,   Singapore,   Sweden,   Switzerland,   United Kingdom,   United States
 
 
NCT00798889
A6181030
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP